Analysts Offer Predictions for ABOS FY2025 Earnings

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Acumen Pharmaceuticals in a note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of ($2.29) per share for the year, down from their previous forecast of ($1.92). The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share. Cantor Fitzgerald also issued estimates for Acumen Pharmaceuticals’ FY2026 earnings at ($1.45) EPS.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14).

Separately, Citigroup began coverage on Acumen Pharmaceuticals in a research note on Tuesday, June 17th. They set a “buy” rating and a $4.00 price objective for the company.

Acumen Pharmaceuticals Stock Performance

Shares of Acumen Pharmaceuticals stock opened at $1.42 on Friday. The firm has a fifty day moving average of $1.32 and a two-hundred day moving average of $1.22. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.02 and a current ratio of 5.97. The stock has a market capitalization of $86.01 million, a price-to-earnings ratio of -0.62 and a beta of 0.14. Acumen Pharmaceuticals has a 52 week low of $0.86 and a 52 week high of $3.36.

Institutional Trading of Acumen Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in shares of Acumen Pharmaceuticals by 1,387.2% in the fourth quarter. JPMorgan Chase & Co. now owns 937,908 shares of the company’s stock worth $1,613,000 after acquiring an additional 874,842 shares in the last quarter. Barclays PLC raised its holdings in Acumen Pharmaceuticals by 50.1% during the 4th quarter. Barclays PLC now owns 93,082 shares of the company’s stock worth $161,000 after buying an additional 31,085 shares during the period. Dimensional Fund Advisors LP raised its holdings in Acumen Pharmaceuticals by 73.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 98,016 shares of the company’s stock worth $169,000 after buying an additional 41,460 shares during the period. Tower Research Capital LLC TRC lifted its stake in Acumen Pharmaceuticals by 427.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 20,624 shares of the company’s stock valued at $35,000 after buying an additional 16,714 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Acumen Pharmaceuticals in the fourth quarter valued at approximately $25,000. 71.01% of the stock is currently owned by institutional investors and hedge funds.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.